Trial Profile
A Randomized Study Comparing MDX-010 (CTLA-4) Alone or in Combination With DTIC in the Treatment of Patients With Chemotherapy Naive Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 16 Feb 2010 New trial record